Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir and camostat mesilate for hospitalized COVID-19 patients
jRCTs031200436Completed
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of favipiravir and camostat mesilate in coronavirus disease 2019 (COVID-19) (3 arms). Primary endpoint: SARS-CoV-2 disappearance at day 10. Started May 2021; status: completed.
02
Drugs
favipiravircamostat mesilate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs031200436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200436.